Display options
Cite
Bertling A, Brodde MF, Visser M, et al. Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4). Transfus Med Hemother. 2017;44(5):351-357doi: 10.1159/000472157.
Bertling, A., Brodde, M. F., Visser, M., Treffon, J., Fennen, M., Fender, A. C., Kelsch, R., & Kehrel, B. E. (2017). Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4). Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 44(5), 351-357. https://doi.org/10.1159/000472157
Bertling, Anne, et al. "Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4)." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 44,5 (2017): 351-357. doi: https://doi.org/10.1159/000472157
Bertling A, Brodde MF, Visser M, Treffon J, Fennen M, Fender AC, Kelsch R, Kehrel BE. Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4). Transfus Med Hemother. 2017 Sep;44(5):351-357. doi: 10.1159/000472157. Epub 2017 Aug 11. PMID: 29070980; PMCID: PMC5649264.
Copy Download .nbib Format: NLM
Share it on

Transfus Med Hemother. 2017 Sep;44(5):351-357. doi: 10.1159/000472157. Epub 2017 Aug 11.

Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4).

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Anne Bertling, Martin F Brodde, Mayken Visser, Janina Treffon, Michelle Fennen, Anke C Fender, Reinhard Kelsch, Beate E Kehrel

Affiliations

  1. Department of Anesthesiology, Intensive Care and Pain Medicine, Experimental and Clinical Hemostasis, University of Münster, Münster, Germany.
  2. OxProtect GmbH, Münster, Germany.
  3. Institute of Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany.
  4. Institute of Transfusion Medicine and Transplantation Immunology, University Hospital Münster, Münster, Germany.

PMID: 29070980 PMCID: PMC5649264 DOI: 10.1159/000472157

Abstract

BACKGROUND: Hemarthrosis, or bleeding into the joints, is a hallmark of hemophilia. Heme triggers oxidative stress, inflammation, and destruction of cartilage and bone. The haptoglobin-CD163-heme oxygenase-1 (HO-1) pathway circumvents heme toxicity through enzymatic degradation of heme and transcription of antioxidant genes. Plasma-derived factor concentrates contain many proteins that might impact on cellular pathways in joints, blood, and vessels.

METHODS: Activation of platelets from healthy volunteers was assessed by flow cytometry analysis of fibrinogen binding and CD62P expression. Platelet CXCL4 release was measured by ELISA. Human peripheral blood mononuclear cells were exposed to CXCL4 or platelet supernatants (untreated or pre-stimulated with factor VIII (FVIII) products) during their differentiation to macrophages and analyzed for CD163 expression. Some macrophage cultures were additionally incubated with autologous hemoglobin for 18 h for analysis of HO-1 expression.

RESULTS: Platelet CXCL4 release was increased by all 8 tested plasma-derived FVIII products but not the 3 recombinant products. Macrophages exposed to supernatant from platelets treated with some plasma-derived FVIII products downregulated CD163 surface expression and failed to upregulate the athero- and joint protective enzyme HO-1 in response to hemoglobin.

CONCLUSION: Plasma-derived FVIII products might promote bleeding-induced joint injury via generation of macrophages that are unable to counteract redox stress.

Keywords: Factor VIII; Hemophilia A; Macrophages; Platelets; Scavenger receptors

References

  1. Nature. 2012 Sep 20;489(7416):456-9 - PubMed
  2. Thromb Haemost. 2014 Nov;112(5):1044-50 - PubMed
  3. Front Physiol. 2012 Jan 13;3:1 - PubMed
  4. Haemophilia. 2012 May;18(3):310-8 - PubMed
  5. Blood. 2000 Feb 15;95(4):1158-66 - PubMed
  6. Haemophilia. 2012 May;18(3):369-74 - PubMed
  7. Thromb Haemost. 2010 Aug;104(2):270-8 - PubMed
  8. J Rheumatol. 1997 Jul;24(7):1350-4 - PubMed
  9. Blood. 1998 Sep 15;92(6):1870-7 - PubMed
  10. Blood. 2002 Aug 1;100(3):912-6 - PubMed
  11. Circulation. 2004 Jul 13;110(2):193-200 - PubMed
  12. Nat Rev Immunol. 2005 Dec;5(12):953-64 - PubMed
  13. Nature. 2001 Jan 11;409(6817):198-201 - PubMed
  14. Circ Res. 2010 Jan 8;106(1):203-11 - PubMed
  15. J Exp Med. 1991 Nov 1;174(5):1209-20 - PubMed
  16. Blood. 2009 Mar 12;113(11):2578-86 - PubMed
  17. Circ Res. 2006 Oct 27;99(9):943-50 - PubMed
  18. Semin Thromb Hemost. 2003 Feb;29(1):37-42 - PubMed
  19. Blood. 2002 Oct 1;100(7):2472-8 - PubMed
  20. Br J Haematol. 1996 Apr;93(1):204-14 - PubMed
  21. Transfus Med Hemother. 2010;37(4):175-184 - PubMed
  22. Blood. 2000 Oct 1;96(7):2469-78 - PubMed
  23. J Bone Joint Surg Br. 1998 May;80(3):540-5 - PubMed
  24. Methods Mol Biol. 2005;290:105-16 - PubMed
  25. J Rheumatol. 1994 Oct;21(10):1802-7 - PubMed
  26. Circ Res. 2004 Jan 9;94(1):119-26 - PubMed
  27. Platelets. 1998;9(3-4):171-7 - PubMed
  28. J Thromb Haemost. 2012 Apr;10(4):647-61 - PubMed
  29. Kidney Int. 2006 Aug;70(3):432-43 - PubMed
  30. Blood. 2004 Oct 1;104(7):2060-4 - PubMed

Publication Types